

BRIEF | Intelligent Investment

Capital Recap: Strong tech investment leads to another \$2 billion quarter

San Diego Marketflash

OVERALL TRENDS

- San Diego companies raised \$2.32 billion in venture capital (VC) funding in Q3 2021, the third highest quarter of funding raised on record slightly above \$2.0 billion in Q2 2021.
- Life science companies brought in \$1.24 billion, the fourth highest quarter of life science funding raised, slightly below last quarter's raise of \$1.54 billion. Biotech/pharma raised the majority with \$998.9 million, generated primarily by two deals of \$100.0 million or greater.
- Tech companies raised \$1.02 billion in the quarter, the highest funding raised on record, significantly higher than last quarter's \$359.8 million. Tech venture capital funding in 2021 YTD is already above what was raised in 2020, and well above 2019. This is in line with a continuing upward trend of interest and investment in the tech sector starting in 2018. Tech (Hardware/Svcs) companies raised most of the tech funding with \$583.2 million. Tech activity in Q3 included sixteen deals of \$10.0 million or greater, five of which were over \$50.0 million.

MAJOR VC DEALS

. Tech funding ramps up in Q3 led by hardware and software companies: Shield AI, a developer of AI to enable fully autonomous unmanned systems that reduce risk and enhance situational awareness in dangerous situations. led Q3's tech funding by raising **\$210.0 million** in Series D. The funding will be used to help scale and further integrate its self-driving software, Hivemind, into additional platforms across the Defense industry. Wiliot, which develops tiny, sticker sized sensors that are disposable, battery free, get its energy from radio waves, and transmit bluetooth, raised \$200.0 million in Series C funding. This latest infusion of funding will be used to ramp up the rollout of battery-free sensor tags and novel, AI-based sensing as a service business model. Seismic, a software company for managing, automating, and distributing sales content, raised \$170.0 million in Series G funding. The company intends to use the funds to continue expanding its platform, R&D, and global presence. Via PRNewsWire, UTSanDiego, and **Finsmes**

Q3 2021 VC Funding



Life Sciences Funding

\$1.24B

Tech Funding

\$1.02B

Life Sciences funding not slowing down: Genomatica, a developer of commercial biobased processes to make widely-used chemicals to enable better, more sustainable everyday products, raised \$118.0 million in Series C funding. The funding will be used to accelerate the commercialization of its suite of sustainable materials. Expansion Therapeutics, which focuses on developing transformative oral medicines for severe RNA-mediated diseases, raised \$80.0 million in Series B funding. The funding will be used to accelerate research. ADARx Pharmaceuticals, which focuses on messenger RNA base-editing, raised \$75.0 million in Series B funding. The proceeds will also be used to transition ADARx's growing pipeline of research phase products into the clinic, including initiation of a Phase 1 clinical trial for ADARx's lead program. Via SDBJ, BusinessWire, and MarketScreener

OTHER INVESTMENT NEWS

- Erasca, a company focused on designing an AI platform that will help in development of oncology drugs to treatment and eventually eliminate cancer, raised \$300.0 million in its IPO. Tyra Biosciences, a developer of tyrosine kinase inhibitors, a class of drugs designed to stop cancers from metastasizing, raised \$172.8 million in its IPO. Inmune BIO, focused on reengineering the immune system to stop cancer recurrence, raised \$40.0 million in its IPO. Via <u>MedCityNews</u>, <u>PRNewsWire</u>, and <u>Inmune Bio</u>
- La Jolla-based startup Ensysce Biosciences, a clinical stage biotech company committed to stemming the prescription drug abuse epidemic, announced that it has closed its previously announced merger with Leisure Acquisition Corp, for \$207.0 million. Via <u>SDBJ</u>




Figure 1: Venture Capital Investment in San Diego County

Dollar and Deal Volume, by Industry Group, Three Years, Q3 2018 to Q3 2021

Source: CBRE Research, with partial data from PwC/CB Insights MoneyTree Report and Crunchbase

Figure 2 Venture Capital Investment in San Diego County

By Industry (Q3 2021 to Four-Quarter Average Comparison)

| 5 5 (| | 0 1 / | | |
|----------------------|-----------------------|------------------------------------|------------------------------|------------------------|
| Industry | # Deals in Q3 2021 | Total Invested in Q3 2021 (\$M) | Trailing 4-Qtr Avg. (\$M) | +/- from Avg. (\$M) |
| Biotech / Pharma | 24 | \$998.9 | \$1,436.0 | - \$437.0 |
| Software / Web | 20 | \$435.1 | \$467.3 | -\$32.2 |
| Tech (Hardware/Svcs) | 7 | \$583.2 | \$201.1 | +\$382.2 |
| Medical Devices | 6 | \$236.4 | \$144.8 | +\$91.6 |
| Remainder | 12 | \$63.3 | \$76.3 | -\$13.0 |
| Total | 69 | \$2,317.0 | \$2,325.4 | -\$8.4 |

Source: CBRE Research, with partial data from PwC/CB Insights MoneyTree Report and Crunchbase